Therapeutic options for the management of abnormal uterine bleeding

被引:9
作者
MacGregor, Becky [1 ]
Munro, Malcolm G. [2 ]
Lumsden, Mary Ann [3 ,4 ,5 ]
机构
[1] Univ Warwick, Warwick Med Sch, Warwick, England
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA
[3] Univ Glasgow, Glasgow City, Scotland
[4] FIGO, London, England
[5] FIGO House, 10 Theed St, London SE1 8ST, England
关键词
fibroids; GnRH agonists; antagonists; leiomyoma; myomectomy; radiological treatments; sex steroids; treatment; LEVONORGESTREL INTRAUTERINE SYSTEM; RANDOMIZED CONTROLLED-TRIAL; TRANEXAMIC ACID TREATMENT; ADD-BACK THERAPY; ARTERY EMBOLIZATION; ENDOMETRIAL ABLATION; ULIPRISTAL ACETATE; HYSTEROSCOPIC MYOMECTOMY; SURGICAL-MANAGEMENT; MEDICAL-MANAGEMENT;
D O I
10.1002/ijgo.14947
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Just as the investigation of abnormal uterine bleeding (AUB) is approached systematically using the two FIGO systems for AUB in the reproductive years, treatment options can be considered similarly. Therapeutic options fall into two categories-medical and surgical-and while medical management is typically regarded as first-line therapy, there are several exceptions defined by the presenting cause or causes, mainly when infertility is a concurrent issue. In the early 1990s, up to 60% of women underwent a hysterectomy for the symptom of heavy menstrual bleeding (HMB), but this figure has decreased. The number of women undergoing a hysterectomy for benign disorders continues to decline, along with an increase in hysterectomies performed using minimally invasive techniques. Discussions about therapeutic options are tailored to the individual patient, and we include the risks and benefits of each option, including no management, to enable the patient to make an informed choice. The different types of treatment options and the factors affecting decision-making are considered in this article.
引用
收藏
页码:43 / 57
页数:15
相关论文
共 144 条
[2]   Surgical approach to hysterectomy for benign gynaecological disease [J].
Aarts, Johanna W. M. ;
Nieboer, Theodoor E. ;
Johnson, Neil ;
Tavender, Emma ;
Garry, Ray ;
Mol, Ben Willem J. ;
Kluivers, Kirsten B. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (08)
[3]   Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis, diagnosis, and management [J].
Abbott, Jason A. .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 40 :68-81
[4]   Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients [J].
Aimagambetova, Gulzhanat ;
Terzic, Sanja ;
Lagana, Antonio Simone ;
Bapayeva, Gauri ;
la Fleur, Philip ;
Terzic, Milan .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (01)
[5]   Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy [J].
Al-Hendy, Ayman ;
Lukes, Andrea S. ;
Poindexter, Alfred N., III ;
Venturella, Roberta ;
Villarroel, Claudio ;
Critchley, Hilary O. D. ;
Li, Yulan ;
McKain, Laura ;
Ferreira, Juan C. Arjona ;
Langenberg, Andria G. M. ;
Wagman, Rachel B. ;
Stewart, Elizabeth A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07) :630-642
[6]   Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women [J].
Ali, Mohamed ;
Sara, A. R. ;
Al Hendy, Ayman .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (04) :427-437
[7]  
American College of Obstetricians and Gynecologists' Committee on Practice BulletinsGynecology, 2018, Obstet Gynecol, V131, pe157, DOI [10.1097/aog.0000000000002657, 10.1097/AOG.0000000000002656]
[8]   Themanagement of endometrial polyps in the 21st century [J].
Annan, John Jude ;
Aquilina, Joseph ;
Ball, Elizabeth .
OBSTETRICIAN & GYNAECOLOGIST, 2012, 14 (01) :33-38
[9]  
[Anonymous], 2013, Obstet Gynecol, V122, P176, DOI 10.1097/01.AOG.0000431815.52679.bb
[10]  
[Anonymous], 2018, HEAV MENSTR BLEED AS